NeuroScientific Biopharmaceuticals has appointed Southern Star Research to conduct a phase two clinical trial for its StemSmart therapy for Crohn’s disease. Reports say the study is planned across Australia and the United States.
The companies describe the trial as part of advancing StemSmart for people with Crohn’s disease, including those with refractory disease. One outlet frames the program within the broader context of a large global market for Crohn’s therapies, while others focus more on the research arrangement and trial stage.
Overall, coverage agrees on the key development: Southern Star Research is hired to run the phase two study, and the trial location includes Australia and the US. Differences in emphasis largely relate to market potential and the specific patient subgroup mentioned (refractory Crohn’s disease), rather than the core facts of the appointment and trial planning.
